Grifols - About the company
Grifols is a public company based in Barcelona (Spain), founded in 1909. It operates as a Developer of plasma-derived therapies to treat multiple diseases. Grifols has raised an undisclosed amount in funding. The company has 442 active competitors, including 136 funded and 120 that have exited. Its top competitors include companies like Biogen, BeiGene and argenx.
Company Details
Developer of plasma-derived therapies to treat multiple diseases. The company focuses on the development of plasma-derived medicines and transfusion medicines for a broad range of therapeutic areas such as neurology, immunology, hepatology and intensive care, pulmonology, hematology, and infectious diseases.
- Website
- www.grifols.com/en/home
- Social
- Email ID
- *****@grifols.com
- Phone Number
- +34 **********
- Registered Address
- Praha
Key Metrics
Founded Year
1909
Location
Barcelona, Spain
Stage
Public
Latest Funding Round
Investors
Ranked
29th among 442 active competitors
Employee Count
14,519 as on Sep 30, 2026
Exit Details
Public
Legal entities associated with Grifols
Grifols is associated with 4 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
WBC, s.r.o. CIN: 46901841 , Czech Republic, Active | May 15, 1992 | - | - | |
Itorias group s.r.o. CIN: 05344751 , Czech Republic, Active | Aug 29, 2016 | - | - | |
GRIFOLS INDIA HEALTHCARE PRIVATE LIMITED CIN: U74999HR2014FTC074802 , India, Active | Dec 20, 2014 | ₹100 - ₹500 Cr (As on Mar 31, 2025) | 16 (As on May 01, 2021) | |
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. CIN: 202533768 , United States, Active | Dec 31, 1999 | - | 14482 (As on Dec 31, 2024) | - |
Grifols's IPO details
Grifols got listed on Jun 10, 2011.
Click here to take a look at Grifols's IPO in detail
Sign up to download Grifols' company profile
Grifols's funding and investors
Grifols has raised funding over 1 round. Its latest funding round was a Grant (prize money) round on Jan 15, 2025 for $*****. 1 investor participated in its latest round. Grifols has 5 institutional investors.
Here is the list of recent funding rounds of Grifols:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 15, 2025 | 9575740 | Grant (prize money) | 9626617 | 2589340 | 4374649 | 7058743 |
Access funding benchmarks and valuations. Sign up today!View details of Grifols's funding rounds and investors
Grifols' founders and board of directors
Founder? Claim ProfileGrifols' employee count trend
Grifols has 14,519 employees as of Sep 26. Here is Grifols's employee count trend over the years:
Uncover Grifols' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Grifols's Competitors and alternates
Top competitors of Grifols include Biogen, BeiGene and argenx. Here is the list of Top 10 competitors of Grifols, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Biogen 1978, Cambridge (United States), Public | Developer of therapies for neurodegenerative and immunology disorders | $80M | 78/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 77/100 | |
3rd | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | 76/100 | ||
4th | Developer of immunotherapeutics for the treatment of cancer and other diseases | $861M | 71/100 | ||
5th | Immunocore 2008, Abingdon (United Kingdom), Public | Developer of bispecific T cell receptor therapies for human diseases | $601M | 70/100 | |
6th | Ionis 1989, United States, Public | Developer of RNA-targeted medicines for various diseases | - | 69/100 | |
7th | DBV Technologies 2002, Bagneux (France), Public | Developer of products for the treatment of various kinds of food allergies | $68.9M | 68/100 | |
8th |  Vera Therapeutics 2016, San Francisco (United States), Public | Developer of therapeutic solutions for the treatment of immunological and inflammatory diseases | $117M | 68/100 | |
9th |  Cabaletta Bio 2017, Radnor (United States), Public | Developer of CAAR T cells for B cell-mediated autoimmune diseases | $88.3M | 68/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 68/100 | |
29th | Developer of plasma-derived therapies to treat multiple diseases | - | 63/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Grifols's competitors? Click here to see the top ones
Grifols's Investments and acquisitions
Grifols has made 4 investments in companies including Iberboard and Singulex. Grifols has also acquired 8 companies including Biotest and GigaGen.Here is the list of investments & acquisitions:
Filter this list
Filter this listDate of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Sep 17, 2021 | Acquisition | 1946 | Dreieich (Germany) | |
Mar 09, 2021 | Acquisition | 2011 | San Francisco (United States) | |
Sep 07, 2020 | Acquisition | 2014 | San Carlos (United States) |
Want to know more about where corporates are investing? Sign up today!See all investments and acquisitions by Grifols
Reports related to Grifols
Here is the latest report on Grifols's sector:
News related to Grifols
Filter this listMedia has covered Grifols for a total of 44 events in the last 1 year, 17 of them have been about company updates and 3 about people movement.
•
Grifols reports Q3 revenue of €2.04 billion, increasing net profit by 28%La Opinión A Coruña•Nov 02, 2026•Grifols
•
Grifols and Engie ink 10-year renewable energy PPA in SpainRenewables Now•Sep 17, 2026•Engie, Grifols, CWG
•
Armistice Capital Among Institutional Holders as Grifols Posts Double-Digit Immunoglobulin Growth in First Half of 2026Tech Times•Aug 19, 2026•Grifols
•
•
OPSEU/SEFPO Calls for End to For-Profit Plasma Collection, Cites Safety Concerns with GrifolsGlobeNewswire•Aug 14, 2026•Grifols
•
Grifols Completes Patient Follow-Up in SPARTA Phase 3 Outcomes Study for Prolastin®-CGlobeNewswire•Aug 10, 2026•Grifols
•
FOXO Technologies Inc.'s Subsidiary Vector BioSource Inc. Acquires Four Blood Collection Centers from Grifols Bio Supplies Inc.GlobeNewswire•Jul 29, 2026•Grifols, FOXO Technologies, Foxo
•
Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship ImmunoglobulinsGlobeNewswire•Jul 16, 2026•Grifols
•
El Ibex 35 closes flat, saving 19,300 points as crude oil hovers around $85 amid conflictCapital•Jul 14, 2026•Ohla, Repsol, Amadeus, Bank of America and 8 others
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Grifols
Explore our recently published companies
- Saalfo Tech - Mysuru based, 2016 founded, Unfunded company
- Tolia - Thane based, 1979 founded, Unfunded company
- Krishna's Herbal & Ayurveda - Jodhpur based, 2007 founded, Unfunded company
- Bregma Science - Bengaluru based, 2016 founded, Unfunded company
- http://nordible.co - Unfunded company
- Transformative Biotech - Boulder based, 2023 founded, Unfunded company
